<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247217</url>
  </required_header>
  <id_info>
    <org_study_id>PRIMUS</org_study_id>
    <nct_id>NCT04247217</nct_id>
  </id_info>
  <brief_title>Immune Profiling After HDR in Local Relapsed Prostate Cancer</brief_title>
  <acronym>PRIMUS</acronym>
  <official_title>Prostate Cancer Immune Profiling Before, During and After HDR-brachytherapy in Local Relapsed Prostate Cancer (PRIMUS-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer&#xD;
      until now fails to respond to classical IO, like PD-1 and CTLA-4 inhibitors. Radiotherapy&#xD;
      (RT) delivered to the primary tumor impacts both tumor cells and surrounding stromal cells.&#xD;
      Radiation damage to cancer cells exposes tumor-specific antigens leading to increased&#xD;
      visibility to the immune system by improved priming and activation of cytotoxic T cells.&#xD;
      RT-induced modulation of the tumor microenvironment may also facilitate the recruitment and&#xD;
      infiltration of immune cells by increasing the expression or T-cell attracting chemokines and&#xD;
      by increasing T-cell docking molecules on the endothelial cells like VCAM-1. The&#xD;
      main-hypothesis is that HDR-brachytherapy will turn an immunologically &quot;cold&quot; (no T-cell&#xD;
      infiltrations) prostate cancer into an immunologically &quot;hot&quot; (CD4 and CD8-cell infiltrations)&#xD;
      tumor, creating leverage points for different forms of IO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective analysis of biopsies from 10 patients with local recurrence in the prostate&#xD;
      selected for salvage HDR brachytherapy in MAASTRO Clinic, Maastricht. HDR treatment is&#xD;
      standard in Maastro Clinic for local relapses of prostate cancer after previously irradiation&#xD;
      (internal or external).&#xD;
&#xD;
      Biopsies will be taken at 4 different time points (before and after the 1st fraction; before&#xD;
      the 2nd and 3rd fraction of the salvage treatment).&#xD;
&#xD;
      Several immunotyping (expression of PD-(L)-1, CXCL12, IL-23 receptor, etc.) and HLA class I&#xD;
      expression will be performed on the biopsies. In addition, HLA genotypes will be determined&#xD;
      on DNA isolated from pheripheral blood.&#xD;
&#xD;
      The plasma and the biopsies will be stored for eventually additional research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of PD-(L)-1 receptor</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Expression of PD-(L)-1 receptor induced by HDR-brachytherapy in prostate tumor biopsies of local relapses of prostate cancer of 10 patients at 4 different time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression patterns of CXCL12</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression patterns of IL-23</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression patterns of MDSC</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in T cell infiltration profiles</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HLA class I-A expression on tumor cells</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HLA class I-B expression on tumor cells</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HLA class I-C expression on tumor cells</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>PD-L1</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR salvage brachytherapy</intervention_name>
    <description>In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.</description>
    <other_name>biopsies</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial&#xD;
      biopsies will be performed at 4 different time points. Furthermore, peripheral blood samples&#xD;
      during anesthesia will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with local relapse of prostate cancer, who are candidate for a salvage HDR&#xD;
        treatment will be asked to participate in this study at the time of intake.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Local relapse of prostate cancer, who is candidate for a salvage HDR treatment:&#xD;
&#xD;
          -  Biochemical relapse (PSA increase)&#xD;
&#xD;
          -  Local relapse on imaging: PSMA scan, mp-MRI&#xD;
&#xD;
          -  Pathology proven relapse&#xD;
&#xD;
               -  Willing and able to comply with the study prescriptions.&#xD;
&#xD;
               -  18 years or older&#xD;
&#xD;
               -  Before patient registration, written informed consent must be given according to&#xD;
                  ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not eligible for proposed (HDR brachytherapy) treatment:&#xD;
&#xD;
               -  Life expectancy &lt; 10 years&#xD;
&#xD;
               -  Distant Metastasis&#xD;
&#xD;
               -  Recently TURP with big urethral defect&#xD;
&#xD;
               -  Not able to stop anticoagulants&#xD;
&#xD;
               -  Flow &lt; 10 ml/sec â€¢ No compliance to study procedure&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>prostate tumor biopsies</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ben Vanneste, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ben Vanneste, MD, PhD</last_name>
    <phone>0031 884455600</phone>
    <email>ben.vanneste@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rody Zuidema</last_name>
    <phone>0031 884455600</phone>
    <email>rody.zuidema@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastro</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Vanneste, MD, PhD</last_name>
      <phone>+31 88 44 55 600</phone>
      <email>ben.vanneste@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Rody Zuidema</last_name>
      <phone>+31 88 44 55 886</phone>
      <email>rody.zuidema@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Vanneste</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

